CompletedNCT03539887
Intranasal Ketamine for Suicidal Thoughts With Depression or Bipolarity
About this title
Read the official source — NCT03539887Medication studyAges 21–60United States
Understand this study
Who was this study for?
Listed age limits: 21 years to 60 years.
- Listed locations
- HoustonSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: May 1, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 33
- Sponsor
- The University of Texas Health Science Center, Houston
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 21 Years to 60 Years
- Official registry ID
- NCT03539887
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Houston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is The University of Texas Health Science Center, Houston, a university.
Did this study involve medication?
Yes. The study involved medication, including Intranasal ketamine and Placebo.
Who was this study for?
Listed age limits: 21 years to 60 years.
